The relationship between inhibitors of the Wnt signalling pathway (sclerostin and Dickkopf-1) and carotid intima-media thickness in postmenopausal women with type 2 diabetes mellitus

Diabetes and Vascular Disease Research

Volumn 11, Issue 1, 2014, Pages 48-52

  Gaudio, Agostino ^a   Privitera, Filippo ^a   Pulvirenti, Ivana ^a   Canzonieri, Elena ^a   Rapisarda, Rosario ^a   Fiore, Carmelo E ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

CIMT; Dkk 1; Sclerostin; type 2 diabetes

Indexed keywords

BETA CATENIN; DICKKOPF 1 PROTEIN; SCLEROSTIN; WNT PROTEIN;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; B SCAN; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; SOLID; WNT SIGNALING PATHWAY;

CIMT; DKK-1; SCLEROSTIN; TYPE 2 DIABETES;

AGED; ALLOSTASIS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BONE MORPHOGENETIC PROTEINS; CAROTID ARTERIES; CAROTID INTIMA-MEDIA THICKNESS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; EARLY DIAGNOSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC MARKERS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MIDDLE AGED; POSTMENOPAUSE; UP-REGULATION; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84890450506     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164113510923     Document Type: Article

References (29)

1. Chen NX, Moe SM. Arterial calcification in diabetes. Curr Diab Rep. 2003 ; 3: 28-32
2. Fujishima M, Kiyohara Y, Kato I, et al. Diabetes and cardiovascular disease in a prospective population survey in Japan: the Hisayama Study. Diabetes. 1996 ; 45: S14 - S16
3. Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998 ; 339: 229-234
4. Madonna R, De Caterina R. Cellular and molecular mechanisms of vascular injury in diabetes. Part I: pathways of vascular disease in diabetes. Vascul Pharmacol. 2011 ; 54: 68-74
5. Schwartz Ann V. Clinical aspects of diabetic bone disease: an update. Clin Rev Bone Miner Metabol. 2013 ; 11: 17-27
6. Hampson G, Edwards S, Conroy S, et al. The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women. Bone. 2013 ; 56: 42-47
7. Reis M, Liebner S. Wnt signaling in the vasculature. Exp Cell Res. 2013 ; 319: 1317-1323
8. Caira FC, Stock SR, Gleason TG, et al. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol. 2006 ; 47: 1707-1712
9. Shao JS, Cheng SL, Pingsterhaus JM, et al. Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest. 2005 ; 115: 1210-1220
10. Dwivedi A, Slater SC, George SJ. MMP-9 and -12 cause N-cadherin shedding and thereby beta-catenin signalling and vascular smooth muscle cell proliferation. Cardiovasc Res. 2009 ; 81: 178-186
11. Johnson ML, Rajamannan N. Diseases of Wnt signaling. Rev Endocr Metab Disord. 2006 ; 7: 41-49
12. Thambiah S, Roplekar R, Manghat P, et al. Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif Tissue Int. 2012 ; 90: 473-480
13. García-Martín A, Rozas-Moreno P, Reyes-García R, et al. Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012 ; 97: 234-241
14. Van Lierop AH, Hamdy NA, Van der Meer RW, et al. Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus. Eur J Endocrinol. 2012 ; 166: 711-716
15. Gennari L, Merlotti D, Valenti R, et al. Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab. 2012 ; 97: 1737-1744
16. Gaudio A, Privitera F, Battaglia K, et al. Sclerostin levels associated with inhibition of the Wnt/β-catenin signaling and reduced bone turnover in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012 ; 97: 3744-3750
17. Morales-Santana S, García-Fontana B, García-Martín A, et al. Atherosclerotic disease in type 2 diabetes is associated with an increase in sclerostin levels. Diabetes Care. 2013 ; 36: 1667-1674
18. Bauer M, Caviezel S, Teynor A, et al. Carotid intima-media thickness as a biomarker of subclinical atherosclerosis. Swiss Med Wkly. 2012 ; 142 :
19. Van den Oord SC, Sijbrands EJ, Ten Kate GL, et al. Carotid intima-media thickness for cardiovascular risk assessment: systematic review and meta-analysis. Atherosclerosis. 2013 ; 228: 1-11
20. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2005 ; 28: S37 - S42
21. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 ; 150: 604-612
22. Nambi V, Chambless L, Folsom AR, et al. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk in Communities) study. J Am Coll Cardiol. 2010 ; 55: 1600-1607
23. Mödder UI, Hoey KA, Amin S, et al. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res. 2011 ; 26: 373-379
24. Laurent S, Cockcroft J, van Bortel L, et al. European Network for Non-invasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006 ; 27: 2588-2605
25. Kim JH, Liu X, Wang J, et al. Wnt signaling in bone formation and its therapeutic potential for bone diseases. Ther Adv Musculoskelet Dis. 2013 ; 5: 13-31
26. Lai CF, Seshadri V, Huang K, et al. An osteopontin-NADPH oxidase signaling cascade promotes pro-matrix metalloproteinase 9 activation in aortic mesenchymal cells. Circ Res. 2006 ; 98: 1479-1489
27. Quasnichka H, Slater SC, Beeching CA, et al. Regulation of smooth muscle cell proliferation by beta-catenin/T-cell factor signaling involves modulation of cyclin D1 and p21 expression. Circ Res. 2006 ; 99: 1329-1337
28. Funato Y, Michiue T, Asashima M, et al. The thioredoxin-related redox-regulating protein nucleoredoxin inhibits Wnt-beta-catenin signalling through dishevelled. Nat Cell Biol. 2006 ; 8: 501-508
29. Claes KJ, Viaene L, Heye S, et al. Sclerostin: another vascular calcification inhibitor?. J Clin Endocrinol Metab. :